Abstract:TNF receptor-associated factor 2 (TRAF2) is documented to regulate tumor development and progression. Currently, the effect of TRAF2 on growth of androgen-refractory prostate cancer in response to TRAIL and the molecular mechanisms are not well understood. Here, we aim to investigate the effect of TRAF2 on in vitro growth of human androgen-insensitive prostate cancer DU-145 cells in the presence of TRAIL. Bioinformatics analysis of the Cancer Genome Atlas (TCGA) data was performed to examine TRAF2 expression and the prognostic value in prostate cancer. Microarray data of GSE21032 dataset were downloaded from Gene Expression Omnibus (GEO) to explore TRAF2 expression in metastatic prostate cancer. Bioinformatics analysis was further conducted to investigate the association of TRAF2 expression with recurrence-free survival in prostate cancer patients. Colony formation, cell viability, and Annexin V/PI apoptosis assays were performed to investigate the effect of TRAF2 on in vitro growth and apoptosis in TRAIL-treated DU-145 cells. The expression levels of mRNA and protein were detected by quantitative RT-PCR and immunoblotting assays. Bioinformatics analysis indicated that TRAF2 expression is significantly upregulated in prostate cancer patients with high Gleason scores (GS>7) compared with those with low Gleason scores (GS≤7). Upregulation of TRAF2 expression is significantly associated with recurrence-free survival in patients. In addition, TRAF2 knockdown can enhance apoptosis and downregulate SIRT1 expression in TRAIL-treated DU-145 cells. In vitro experiments further showed that SIRT1 knockdown can inhibit growth, and promote apoptosis in TRAIL-treated DU-145 cells. Overall, TRAF2 can influence in vitro growth of TRAIL-treated DU-145 cells at least partially via regulating SIRT1 expression, and may be a potentially valuable biomarker predicting recurrence-free survival in prostate cancer patients.

Abstract 4277: TRAF2 is a key mediator of the EGF-induced signaling pathway.

Tumor Necrosis Factor Receptor-associated Factor Family Protein 2 is a Key Mediator of the Epidermal Growth Factor-induced Ribosomal S6 Kinase 2/Camp-Responsive Element-binding Protein/Fos Protein Signaling Pathway*

T cell development involves TRAF3IP3-mediated ERK signaling in the Golgi.

TRAF3 regulates the effector function of regulatory T cells and humoral immune responses.

TRAF2: a Double-Edged Sword?

TRAF1 is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis.

Role of TRAF2 in AP-1 Signaling Pathway of Human B Cells

Physiological Roles and Mechanisms of Signaling by TRAF2 and TRAF5

Sphingosine Kinase Interacts with TRAF2 and Dissects Tumor Necrosis Factor-α Signaling

Protein-Protein Interactions in TRAF3

Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor κB and Mitogen-Activated Protein Kinase Pathways

The Evolving Role of TRAFs in Mediating Inflammatory Responses

Direct Activation of TACE-Mediated Ectodomain Shedding by P38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation

Selective disruption of Traf1/cIAP2 interaction attenuates inflammatory responses and limits sepsis and rheumatoid arthritis

RSK2 is Required for TRAF6 Phosphorylation-Mediated Colon Inflammation

The role of TRAF2 in activation of NF-kB signaling pathway in hmnan B lymphocytes

K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR

Inhibition Of The Rsk2-Atf1 Signaling Axis By Eriodictyol Suppresses Neoplastic Cell Transformation

Knockdown of TNF Receptor-Associated Factor 2 (TRAF2) Modulates in Vitro Growth of TRAIL-treated Prostate Cancer Cells.

Revisited role of TRAF2 and TRAF2 C-terminal domain in endoplasmic reticulum stress-induced autophagy in HAP1 leukemia cells

Epidermal Growth Factor (EGF) Receptor Kinase Activity is Required for Tumor Necrosis Factor (TNF)-α Mediated Intestinal Epithelial Survival